Drug
incobotulinumtoxin A
incobotulinumtoxin A is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
active_not_recruiting125%
completed375%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
NCT05456087
completedphase_2
Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
NCT02107261
completedphase_2
Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)
NCT02728778
completed
Retrospective Evaluation of Combination Treatment With the Ulthera System
NCT02444169
Clinical Trials (4)
Showing 4 of 4 trials
NCT05456087Phase 2
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
NCT02107261Phase 2
Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
NCT02728778Phase 2
Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)
NCT02444169
Retrospective Evaluation of Combination Treatment With the Ulthera System
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4